$105.64
Abbott Laboratories is a medical devices business with stocks listed in the US. Abbott Laboratories shares (ABT) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$105.9 – a decrease of 1.28% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in Abbott Laboratories
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Abbott Laboratories. Find the share by name or ticker symbol: ABT. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Abbott Laboratories reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$105.9, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Abbott Laboratories, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Abbott Laboratories. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
Our top pick for
US stocks
Our top pick for
Best for beginner
Our top pick for
Dividend investing
Abbott Laboratories stock price (NYSE:ABT)
Use our graph to track the performance of ABT stocks over time.Have Abbott Laboratories's shares ever split?
Abbott Laboratories's shares were split on a 10000:4798 basis on 1 January 2013. So if you had owned 4798 shares the day before the split, the next day you would own 10000 shares. This wouldn't directly have changed the overall worth of your Abbott Laboratories shares – just the quantity. However, indirectly, the new 52% lower share price could have impacted the market appetite for Abbott Laboratories shares which in turn could have impacted Abbott Laboratories's share price.
Abbott Laboratories shares at a glance
52-week range | US$88.7986 - US$121.0397 |
---|---|
50-day moving average | US$113.1636 |
200-day moving average | US$106.6771 |
Target price | US$126.69 |
PE ratio | 33.1122 |
Dividend yield | US$2.12 (2.07%) |
Earnings per share (TTM) | US$3.21 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Abbott Laboratories price performance over time
Historical closes compared with the last close of $105.9
1 week (2024-04-30) | |
---|---|
1 month (2024-04-05) | |
3 months (2024-02-07) | |
6 months (2023-11-07) |
1 year (2023-05-05) | |
---|---|
2 years (2022-05-06) | |
3 years (2021-05-06) | |
5 years (2019-05-07) |
Compare trading platforms to buy Abbott Laboratories shares
Is it a good time to buy Abbott Laboratories stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Abbott Laboratories under- or over-valued?
Valuing Abbott Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abbott Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Abbott Laboratories's P/E ratio
Abbott Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 33x. In other words, Abbott Laboratories shares trade at around 33x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Abbott Laboratories's PEG ratio
Abbott Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.9854. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abbott Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Abbott Laboratories's EBITDA
Abbott Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$10.3 billion (£8.2 billion).
The EBITDA is a measure of a Abbott Laboratories's overall financial performance and is widely used to measure stock profitability.
Abbott Laboratories share price volatility
Over the last 12 months, Abbott Laboratories's shares have ranged in value from as little as US$88.7986 up to US$121.0397. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Abbott Laboratories's is 0.74. This would suggest that Abbott Laboratories's shares are less volatile than average (for this exchange).
Abbott Laboratories financials
Revenue TTM | US$40.3 billion |
---|---|
Operating margin TTM | 14.06% |
Gross profit TTM | US$24.6 billion |
Return on assets TTM | 6.11% |
Return on equity TTM | 15.11% |
Profit margin | 13.96% |
Book value | 22.261 |
Market capitalisation | US$184.4 billion |
TTM: trailing 12 months
Abbott Laboratories share dividends
Dividend payout ratio: 48.29% of net profits
Recently Abbott Laboratories has paid out, on average, around 48.29% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.07% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Abbott Laboratories shareholders could enjoy a 2.07% return on their shares, in the form of dividend payments. In Abbott Laboratories's case, that would currently equate to about $2.12 per share.
While Abbott Laboratories's payout ratio might seem fairly standard, it's worth remembering that Abbott Laboratories may be investing much of the rest of its net profits in future growth.
Abbott Laboratories's most recent dividend payout was on 14 May 2024. The latest dividend was paid out to all shareholders who bought their shares by 11 April 2024 (the "ex-dividend date").
Abbott Laboratories's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Abbott Laboratories.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Abbott Laboratories's total ESG risk score
Total ESG risk: 32.35
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Abbott Laboratories's overall score of 32.35 (as at 12/31/2018) is pretty weak – landing it in it in the 61st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Abbott Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Abbott Laboratories's environmental score
Environmental score: 3.98/100
Abbott Laboratories's environmental score of 3.98 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Abbott Laboratories's social score
Social score: 20.71/100
Abbott Laboratories's social score of 20.71 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Abbott Laboratories's governance score
Governance score: 13.15/100
Abbott Laboratories's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Abbott Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Abbott Laboratories's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Abbott Laboratories scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Abbott Laboratories hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Abbott Laboratories was last rated for ESG on: 2019-01-01.
Total ESG score | 32.35 |
---|---|
Total ESG percentile | 60.66 |
Environmental score | 3.98 |
Environmental score percentile | 5 |
Social score | 20.71 |
Social score percentile | 5 |
Governance score | 13.15 |
Governance score percentile | 5 |
Level of controversy | 3 |
Abbott Laboratories overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Stocks similar to Abbott Laboratories
Abbott Laboratories in the news
Roche (RHHBY) Launches AI-Based Predictive CGM Accu-Chek
Abbott Extends Innovative Health Partnership With Real Madrid and the Real Madrid Foundation
Dexcom Breaks Out As FDA Clears It To Enter A New Market: Obesity
Frequently asked questions
More guides on Finder
-
How to buy Tasmea Limited shares
Steps to owning and managing Tasmea Limited shares.
-
Bendigo Invest Direct share trading review
Your in-depth review of the Bendigo Invest Direct share trading service and what it offers for Aussie investors.
-
The best ASX shares to buy now in 2024? (May update)
Here are our algorithm-selected 20 Aussie stocks worth watching in 2024.
-
How to buy Gol Linhas Aereas Inteligentes SA ADR (GOL) shares in Australia
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
-
Best dividend stocks on the ASX for 2024
Following a couple of lean years for dividend investors, here are 20 ideas you could consider in your portfolio.
-
Interactive Brokers Australia review
Earn interest on your cash balance and enjoy competitive brokerage fees from just $6 with Interactive Brokers.
-
Selfwealth review: Cheap, fixed-fee share trading
SelfWealth online share trading provides easy access to the Australian share market with a flat brokerage fee per trade, no matter the size.
-
GO Markets review: A trading platform for stocks, forex and CFDs
GO Markets offers a comprehensive package to both share investors and experienced CFD traders.
-
Amscot review
With amscot, you get to trade in shares using an online platform or over the phone, while paying competitive fees. Learn more in our amscot review.
-
Bell Direct online share trading platform review
Bell Direct offers one-second placement guarantees for trades, so you can take advantage of all trading opportunities at the price you want.
Ask a Question